Hematologic Effects of Linezolid: Summary of Clinical Experience

Article Properties
  • Language
    English
  • Publication Date
    2002/08/01
  • Indian UGC (Journal)
  • Refrences
    21
  • Citations
    10
  • Stanton L. Gerson Division of Hematology/Oncology and Ireland Cancer Center, Case Western Reserve University & University Hospitals of Cleveland, Cleveland, Ohio
  • Sheldon L. Kaplan Department of Pediatrics, Baylor College of Medicine, Houston, Texas
  • Jon B. Bruss Pharmacia, Kalamazoo, Michigan
  • Vu Le Pharmacia, Kalamazoo, Michigan
  • Felix M. Arellano Pharmacia, Peapack, New Jersey
  • Barry Hafkin Pharmacia, Peapack, New Jersey
  • David J. Kuter Hematology/Oncology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
Abstract
Cite
Gerson, Stanton L., et al. “Hematologic Effects of Linezolid: Summary of Clinical Experience”. Antimicrobial Agents and Chemotherapy, vol. 46, no. 8, 2002, pp. 2723-6, https://doi.org/10.1128/aac.46.8.2723-2726.2002.
Gerson, S. L., Kaplan, S. L., Bruss, J. B., Le, V., Arellano, F. M., Hafkin, B., & Kuter, D. J. (2002). Hematologic Effects of Linezolid: Summary of Clinical Experience. Antimicrobial Agents and Chemotherapy, 46(8), 2723-2726. https://doi.org/10.1128/aac.46.8.2723-2726.2002
Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, et al. Hematologic Effects of Linezolid: Summary of Clinical Experience. Antimicrobial Agents and Chemotherapy. 2002;46(8):2723-6.
Journal Categories
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
Science
Microbiology
Description

What are the potential side effects of Linezolid? This study summarizes clinical trial data to assess the *hematologic effects* of Linezolid, an important antibiotic. This research examines the incidence of anemia, thrombocytopenia, and neutropenia associated with Linezolid treatment. By analyzing clinical trial data, the authors identify potential risks and provide guidance for appropriate monitoring during Linezolid use. The findings indicate that thrombocytopenia and a slightly increased risk of anemia are evident with Linezolid treatment lasting two weeks or more. Hematologic abnormalities are consistent with mild, reversible, duration-dependent myelosuppression. The study highlights the importance of monitoring blood counts during Linezolid therapy. This summary provides valuable information for clinicians prescribing Linezolid. By understanding the potential hematologic effects, healthcare professionals can optimize patient safety and ensure appropriate monitoring strategies are implemented during treatment. This can have a great impact on public health.

As a contribution to Antimicrobial Agents and Chemotherapy, this study directly aligns with the journal's focus on research related to antimicrobial drugs. The paper addresses a critical aspect of antimicrobial therapy by assessing the potential side effects of Linezolid, a widely used antibiotic, adding to the medical data in this area.

Refrences
Citations
Citations Analysis
The first research to cite this article was titled Successful Treatment of Disseminated Bacillus Calmette-Guérin Disease in an HIV-Infected Child with a Linezolid-Containing Regimen and was published in 2016. The most recent citation comes from a 2024 study titled Successful Treatment of Disseminated Bacillus Calmette-Guérin Disease in an HIV-Infected Child with a Linezolid-Containing Regimen . This article reached its peak citation in 2022 , with 3 citations.It has been cited in 8 different journals, 50% of which are open access. Among related journals, the Frontiers in Pharmacology cited this research the most, with 2 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year